68-week results) 2 JAMA Network (2023)Semaglutide (STEP) obesity trials: efficacy and safety data (~15% weight loss at 2.4 mg weekly) 3 The Lancet (2023)Semaglutide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) 4 PubMed / NEJM (2023)Semaglutide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events 5 Metabolites (PMC, 2025)SemaglutideA Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) 6 New England Journal of Medicine (2021)Once-weekly semaglutide 2.4 mg in adults with overweight or obesity (STEP 1, NEJM 2021) 7 PubMed (2025)Meta-analysis: Semaglutide achieves ~14% greater weight reduction vs placebo with no increase in adverse events 8 Molecular Metabolism (2025)Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics 9 Nature Reviews Endocrinology (2024)GLP-1 receptor agonists for obesity and diabetes: a clinical landscape review 10 Journal of Cachexia, Sarcopenia and Muscle (PMC)Protein requirements during weight loss: preserving lean mass 11 GenScriptPeptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) 12 BachemHandling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) 13 Centers for Disease Control and Prevention (CDC)Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) 14 NCBI BookshelfInjection Administration Best Practices (aseptic technique, sharps disposal, and safety) 15 Pharmacologic Considerations of the Subcutaneous Route (PMC)Subcutaneous injection technique and site rotation to prevent lipohypertrophy 16 Prime Lab PeptidesSemaglutide (20 mg) product page (quality documentation and specifications) Semaglutide frequently asked questions How do I reconstitute a 20 mg vial of Semaglutide
Genetics, starting weight, medication dose, insulin resistance, nutrition, sleep quality, and physical activity all influence how quickly your body responds
CIT, L-citrulline
Your muscles contract more efficiently
Understanding Medicare GLP-1 program eligibility is the first step for seniors hoping to access affordable weight-loss medications this year
Randomized controlled trials with liraglutide, semaglutide, albiglutide, and dulaglutide have shown significant reductions in composite cardiovascular outcomes
